Adverum Biotechnologies, Inc. (ADVM)

Latest Insider Confidence Score

2025Q4

50.3
Bullish

Company insider confidence (by quarter)

2014Q3 2025Q4

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Versant Venture Capital IV, L.P. — 7,003,892 May 18, 2016
Versant Ventures IV, LLC — 7,003,892 May 18, 2016
Versant IV Luxco S.a r.l. — 7,003,892 May 18, 2016
Versant Capital IV (Switzerland) GmbH — 7,003,892 May 18, 2016
Frazier Life Sciences Public Fund, L.P. 10% Owner 4,288,949 Dec 5, 2025

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Dec 9, 2025 Dec 10, 2025 Fischer Laurent CEO Neutral 47.5 -399,179 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Soparkar Peter COO Neutral 47.5 -100,647 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Ozden Rabia Gurses Chief Medical Officer Neutral 47.5 -8,125 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 47.5 -66,331 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Rubinstein Linda M CFO Neutral 47.5 -69,275 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Hong Soo Director Neutral 52.5 - 0.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Whitcup Scott M Director Neutral 52.5 - 0.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Tuckson Reed Vaughn Director Neutral 52.5 - 0.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Svoronos Dawn Director Neutral 47.5 -5,000 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Scopa James Paul Director Neutral 47.5 -10,333 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Nicholson, C. David Director Neutral 52.5 - 0.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Lupher, Jr. Mark L. Director Neutral 47.5 -13,000 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Machado Patrick Director Neutral 47.5 -8,818 -100.00% ✗ -
Dec 9, 2025 Dec 10, 2025 Kiss Szilard Director Neutral 52.5 - 0.00% ✗ -
Dec 9, 2025 Dec 9, 2025 Frazier Life Sciences Public Fund, L.P. 10% Owner Sell 15.0 -4,288,949 -100.00% ✗ $15.3M
Dec 5, 2025 Dec 8, 2025 Fischer Laurent CEO Buy 97.5 +128,699 176.75% ✗ $553.9K
Dec 5, 2025 Dec 8, 2025 Soparkar Peter COO Buy 95.0 +50,000 165.62% ✗ $211K
Dec 4, 2025 Dec 5, 2025 Leonard Braden Michael 10% Owner Sell 17.5 -524,560 -19.61% ✗ $2.2M
Dec 5, 2025 Frazier Life Sciences Public Fund, L.P. 10% Owner Neutral 52.5 - 0.00% ✗ -
Dec 1, 2025 Dec 3, 2025 Leonard Braden Michael 10% Owner Sell 17.5 -574,886 -6.64% ✗ $2.4M
Jun 17, 2025 Jun 20, 2025 Soparkar Peter COO Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Rubinstein Linda M CFO Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Ozden Rabia Gurses Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Fischer Laurent CEO Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Kiss Szilard Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Scopa James Paul Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Whitcup Scott M Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Tuckson Reed Vaughn Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Svoronos Dawn Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Lupher, Jr. Mark L. Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Hong Soo Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Nicholson, C. David Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2025 Jun 20, 2025 Machado Patrick Director Neutral 52.5 - 0.00% ✗ -
May 15, 2025 May 16, 2025 Soparkar Peter COO Sell 27.5 -2,960 -7.03% ✗ $5.9K
May 15, 2025 May 16, 2025 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Sell 27.5 -924 -6.29% ✗ $1.8K
May 15, 2025 May 16, 2025 Fischer Laurent CEO Sell 26.3 -9,126 -9.45% ✗ $18.3K
Mar 26, 2025 Apr 28, 2025 Leonard Braden Michael 10% Owner Buy 82.5 +37,000 1.31% ✗ $188.9K
Mar 26, 2025 Apr 28, 2025 Leonard Braden Michael 10% Owner Buy 82.5 +37,000 1.31% ✗ $188.9K
Apr 22, 2025 Apr 24, 2025 Leonard Braden Michael 10% Owner Buy 100.0 +350,000 12.07% ✗ $1M
Mar 31, 2025 Apr 2, 2025 Leonard Braden Michael 10% Owner Buy 72.5 +34,775 0.62% ✗ $147.1K
Mar 26, 2025 Mar 27, 2025 Leonard Braden Michael 10% Owner Buy 56.3 +3,814 0.13% ✗ $16.8K
Mar 18, 2025 Mar 20, 2025 Leonard Braden Michael 10% Owner Buy 85.0 +117,941 2.18% ✗ $587.6K
Feb 26, 2025 Feb 28, 2025 Leonard Braden Michael 10% Owner Buy 100.0 +336,756 14.19% ✗ $1.4M
Feb 25, 2025 Feb 27, 2025 Soparkar Peter COO Neutral 90.0 +13,125 45.28% ✗ -
Feb 25, 2025 Feb 27, 2025 Ozden Rabia Gurses Chief Medical Officer Neutral 90.0 +8,125 100.00% ✗ -
Feb 25, 2025 Feb 27, 2025 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 90.0 +8,125 123.72% ✗ -
Feb 25, 2025 Feb 27, 2025 Fischer Laurent CEO Neutral 90.0 +25,000 34.91% ✗ -
Feb 25, 2025 Feb 27, 2025 Rubinstein Linda M CFO Neutral 90.0 +8,125 72.54% ✗ -
Aug 2, 2024 Aug 6, 2024 Ozden Rabia Gurses Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Aug 2, 2024 Aug 6, 2024 Rubinstein Linda M CFO Neutral 52.5 - 0.00% ✗ -
Aug 2, 2024 Aug 6, 2024 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 52.5 - 0.00% ✗ -
Aug 2, 2024 Aug 6, 2024 Soparkar Peter COO Neutral 52.5 - 0.00% ✗ -
Aug 2, 2024 Aug 6, 2024 Fischer Laurent CEO Neutral 52.5 - 0.00% ✗ -
Jul 30, 2024 Jul 31, 2024 Leonard Braden Michael 10% Owner Buy 90.0 +85,800 3.75% ✗ $613.5K
Jul 18, 2024 Leonard Braden Michael 10% Owner Neutral 52.5 - 0.00% ✗ -
Jul 17, 2024 Jul 18, 2024 Leonard Braden Michael 10% Owner Buy 100.0 +216,264 10.44% ✗ $1.8M
Jun 17, 2024 Jun 20, 2024 Ozden Rabia Gurses Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Nicholson, C. David Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Hong Soo Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Lupher, Jr. Mark L. Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Svoronos Dawn Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Tuckson Reed Vaughn Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Whitcup Scott M Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Scopa James Paul Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Machado Patrick Director Neutral 52.5 - 0.00% ✗ -
Jun 17, 2024 Jun 20, 2024 Kiss Szilard Director Neutral 52.5 - 0.00% ✗ -
Jun 20, 2024 Kiss Szilard Director Neutral 52.5 - 0.00% ✗ -
Oct 3, 2023 Mar 12, 2024 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 52.5 - 0.00% ✗ -
Oct 3, 2023 Mar 12, 2024 Soparkar Peter COO Neutral 52.5 - 0.00% ✗ -
Oct 3, 2023 Mar 12, 2024 Fischer Laurent CEO Neutral 52.5 - 0.00% ✗ -
Feb 12, 2024 Feb 14, 2024 Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER Neutral 52.5 - 0.00% ✗ -
Feb 12, 2024 Feb 14, 2024 Fischer Laurent CEO Neutral 52.5 - 0.00% ✗ -
Feb 12, 2024 Feb 14, 2024 Rubinstein Linda M CFO Neutral 52.5 - 0.00% ✗ -
Feb 12, 2024 Feb 14, 2024 Soparkar Peter COO Neutral 52.5 - 0.00% ✗ -
Feb 7, 2024 Feb 9, 2024 Scopa James Paul Director Buy 95.0 +100,000 2999.40% ✗ $135K
Feb 7, 2024 Feb 9, 2024 Lupher, Jr. Mark L. Director Buy 95.0 +130,000 100.00% ✗ $175.5K
Nov 3, 2023 Nov 6, 2023 Nicholson, C. David Director Neutral 52.5 - 0.00% ✗ -
Nov 6, 2023 Nicholson, C. David Director Neutral 52.5 - 0.00% ✗ -
Sep 15, 2023 Sep 18, 2023 Seyedkazemi Setareh Chief Development Officer Sell 27.5 -6,201 -11.51% ✗ $9.4K
Aug 3, 2023 Sep 5, 2023 Rubinstein Linda M CFO Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Ozden Rabia Gurses Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Scopa James Paul Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Whitcup Scott M Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Tuckson Reed Vaughn Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Svoronos Dawn Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Lupher, Jr. Mark L. Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Hong Soo Director Neutral 52.5 - 0.00% ✗ -
Jun 9, 2023 Jun 13, 2023 Machado Patrick Director Neutral 52.5 - 0.00% ✗ -
Jun 7, 2023 Jun 9, 2023 Rubinstein Linda M CFO Buy 95.0 +100,000 100.00% ✗ $145.5K
Mar 15, 2023 Mar 17, 2023 Riley Brigit Chief Scientific Officer Sell 27.5 -7,299 -5.85% ✗ $5.7K
Mar 15, 2023 Mar 17, 2023 Soparkar Peter COO Sell 26.3 -13,360 -4.78% ✗ $10.4K
Mar 15, 2023 Mar 17, 2023 Fischer Laurent CEO Sell 26.3 -41,239 -5.62% ✗ $32.2K
Mar 1, 2023 Mar 3, 2023 Riley Brigit Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Mar 1, 2023 Mar 3, 2023 Seyedkazemi Setareh Chief Development Officer Neutral 52.5 - 0.00% ✗ -
Mar 1, 2023 Mar 3, 2023 Beckman Richard Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Mar 1, 2023 Mar 3, 2023 Soparkar Peter COO Neutral 52.5 - 0.00% ✗ -
Mar 1, 2023 Mar 3, 2023 Fischer Laurent CEO Neutral 52.5 - 0.00% ✗ -
Dec 15, 2022 Rubinstein Linda M CFO Neutral 52.5 - 0.00% ✗ -
Sep 19, 2022 Sep 21, 2022 Beckman Richard Chief Medical Officer Sell 27.5 -4,272 -9.86% ✗ $4.6K